Glaukos Corp at JPMorgan Healthcare Conference Transcript
Hi, sorry about that. So let's get started. It's closing out this Tuesday. I'm really happy to be introducing members of the management team of Glaukos. We have CEO, Tom Burns; COO, Joe Gilliam; and Alex Thurman, CFO. So we're starting some prepared remarks and then I will join them for a Q&A.
Okay. Thank you. Good evening and thank you for coming here tonight to learn more about Glaukos. Our founding mission at Glaukos has been a device -- a facile implantable injectable procedure that could liberate glaucoma patients from a lifelong consignment to glaucoma for topical drop therapy.
And in doing so, we have really had been from the very beginning -- it's been our birth right -- has been interventional glaucoma. From the beginning, we sought to transform glaucoma therapy by devising a portfolio of products that would treat patients across the full range of glaucoma disease stage severity.
Our two major products within the first five years were iStent and iStent inject,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
